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ABSTRACT 
Introduction 
Invasive pneumococcal disease, including meningitis, caused by Streptococcus pneumoniae 
is a major cause of morbidity and mortality world-wide. The introduction of pneumococcal 
polysaccharide-protein conjugate vaccine (PCV) in the United States has resulted in a 
reduction in incidence of pneumococcal meningitis. PCV was introduced into the South 
African expanded programme on immunization (EPI) in 2009. 
Objective 
We evaluated the temporal association which the introduction of PCV into the South African 
EPI had on the incidence of pneumococcal meningitis in children. 
Methods 
The study was undertaken in Soweto. All children admitted to Chris Hani Baragwanath 
Academic Hospital (CHBAH) <14 years of age with meningitis from January 2006 to 
November 2011 were identified through an electronic database and their microbiological 
records reviewed to identify the causative bacteria. The results were time framed into two 
groups: prior to introduction of PCV 1 January 2006 to 31 March 2009 (pre-vaccine era) and 
post PCV-introduction 1 April 2009 to 30 November 2011 (post-vaccine era). 
Results 
783 patients were admitted with suspected meningitis during the study period, of these 243 
(31.0%) met the criteria for bacterial meningitis. The incidence of pneumococcal meningitis 
was decreasing in the CHBAH in-patient paediatric population by 4.7% per annum prior to 
the introduction of the vaccine in April 2009. The decline in incidence after PCV introduction 
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accelerated to 18% per annum post-vaccine introduction (P=0.391). In the population most at 
risk for pneumococcal meningitis, children <1 year of age, the annual reduction in incidence 
of pneumococcal meningitis accelerated from 1.1% in the pre-vaccine era to 43.4% following 
PCV introduction (P= 0.011).  
Conclusions 
The introduction of PCV resulted in a decline in the incidence of pneumococcal meningitis in 
all age groups. This decline was most dramatic in the <1 year age group.   
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
ACKNOWLEDGEMENTS 
I gratefully acknowledge and thank:  
My supervisors, Professor Shabir Madhi and Dr David Moore. 
Dr Alane Izu for her assistance with the statistical analysis. 
All patients whose data were used in this study. 
The Respiratory and Meningeal Pathogens Unit and staff for their support. 
The Medical Advisory Committee and the Chris Hani Baragwanath Academic Hospital for 
allowing us to conduct our study. 
The National Health Laboratory services, Department of Microbiology.  
The Department of Paediatrics and Child Health and the Faculty of Health Sciences of the 
University of the Witwatersrand. 
 
 
 
 
 
 
 
 
vii 
 
TABLE OF CONTENTS 
 
DECLARATION         ii 
DEDICATION         iii  
ABSTRACT          iv 
ACKNOWLEDGEMENTS        vi 
TABLE OF CONTENTS        vii  
LIST OF FIGURES         viii  
LIST OF TABLES         ix  
ABBREVIATIONS         x  
 
1.0 INTRODUCTION  
 
1.1 Background          1  
1.2 Vaccine review          3 
1.3 Hypothesis and Objectives        5 
 
2.0 METHODS  
 
2.1 Study Population          6 
2.2 Meningitis diagnosis at CHBAH       6 
2.3 Study Method         8 
2.4 Statistical analysis        10 
2.5 Study Approval         11 
 
3.0 RESULTS  
 
3.1 Overall meningitis        12 
3.2 Pneumococcal meningitis        19 
3.3 Trends in the HIV infected population      22 
 
4.0 DISCUSSION         27 
 
5.0 CONCLUSION          32 
 
6.0 APPENDICES         33 
 
7.0 REFERENCES          37 
 
 
viii 
 
LIST OF FIGURES 
 
Figure 1: Annual incidence of meningitis per 100,000 population stratified by  
meningitis type.          14 
 
Figure 2: Regression model for all bacterial meningitis in all age groups.   17   
 
Figure 3: Regression model for all bacterial meningitis in children <1 year of age. 18 
 
Figure 4: Regression model for pneumococcal meningitis in all age groups.  20 
 
Figure 5: Regression model for pneumococcal meningitis in children <1 year of age. 21 
 
 
 
 
 
 
 
 
ix 
 
LIST OF TABLES 
 
Table 1: Demographic data of children with meningitis.     12 
 
Table 2: The number of cases of all bacterial meningitis pathogens during  
the study period.         13 
 
Table 3: Bacterial meningitis by annual quarters in all age groups.   15 
 
Table 4: Bacterial meningitis by annual quarters in children <1 year of age.  15 
 
Table 5: Regression model for all meningitis pre and post vaccine introduction  
in all age groups.         16 
 
Table 6: Regression model for all meningitis pre and post vaccine introduction  
in children <1 year of age.        18 
 
Table 7: Regression model for pneumococcal meningitis pre and post vaccine  
introduction in all age groups.        19 
 
Table 8: Regression model for pneumococcal meningitis pre and post vaccine  
introduction in children <1 year of age.       21 
 
Table 9: Number of cases of pneumococcal meningitis stratified by age  
and HIV status.          24 
 
Table 10: Incidence of pneumococcal meningitis in children <14yrs  
in the Intermediate and Established ART Eras prior to vaccine introduction.  25 
 
Table 11: Incidence of pneumococcal meningitis in children <14yrs in the  
Intermediate and Established ART Eras including years after vaccine introduction. 25 
 
Table 12: Incidence of pneumococcal meningitis in children <1yr in the  
Intermediate and Established ART Eras prior to vaccine introduction.   26 
 
Table 13: Incidence of pneumococcal meningitis in children <1yr in the  
Intermediate and Established ART Eras including years after vaccine introduction. 26 
 
 
 
 
x 
 
ABBREVIATIONS 
ART   Antiretroviral therapy 
BHI  Brain-heart infusion broth 
CHBAH  Chris Hani Baragwanath Academic Hospital 
CSF   Cerebrospinal fluid 
ELISA  Enzyme-linked immunosorbent assay 
EPI   Expanded programme on immunisation 
HIV   Human immunodeficiency virus 
HREC  Human Research Ethics Committee 
IPD   Invasive pneumococcal disease 
MCV1  First dose of measles-containing vaccine  
NHLS   National Health Laboratory Service 
PCR  Polymerase chain reaction 
PCV   Pneumococcal polysaccharide-protein conjugate vaccine 
RMPRU  Respiratory & Meningeal Pathogens Research Unit  
WHO  World Health Organization 
 
 
 
 
1 
 
1.0 Introduction 
1.1 Background 
Bacterial meningitis is an important acute infectious disease of childhood that remains a 
source of substantial morbidity and mortality [1]. A meta-analysis of  bacterial meningitis 
reported an overall case fatality rate of  4.5% [2], and the World Health Organization (WHO) 
estimates that bacterial meningitis causes up to 263,000 deaths in low-income countries 
annually [3].   
One of the most important causes of bacterial meningitis, in the absence of pneumococcal 
polysaccharide-protein conjugate vaccine (PCV), is Streptococcus pneumoniae, a pathogen that 
affects children and adults worldwide. In 2005, the WHO estimated that 0.7-1.0 million 
children under five years of age, mostly in developing countries, died of pneumococcal 
disease annually [4]. Data collected through the Group for Enteric, Respiratory and 
Meningeal Disease Surveillance in South Africa (GERMS-SA) confirms that the age group at 
highest risk of invasive pneumococcal disease (IPD) in the South African setting are infants 
under one year of age [5]. 
A systematic literature review in 2009 estimated the global incidence of pneumococcal 
meningitis in children to be 17 cases per 100,000 [6]. In the United States, the estimated 
overall annual incidence of pneumococcal meningitis prior to PCV immunization was 1-2 
cases per 100,000, with the highest incidence among children 6-24 months of age (3-30 per 
100,000, with a peak of 30 per 100,000 in those 3-5 months of age) [7]. The extent of the 
burden of meningitis is also reflected by the high case fatality rate in the USA (19%) for 
pneumococcal meningitis, where it contributed to 7,600 of 40,000 annual deaths due to  
invasive pneumococcal disease (IPD) prior to PCV-immunization [7]. In South Africa 
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specifically, the case fatality rate was 19% in the period 1991-1992 [8]. This has been 
reflected locally in a review of all bacterial meningitis at Kalafong Hospital over the period 
1990-1995 in which the morbidity and case fatality rate (9.8%) were greatest for S. 
pneumoniae meningitis [9]. A survey of meningitis throughout Africa found a case fatality 
rate of 45% for pneumococcal meningitis and long term sequelae in 50% of surviving cases 
[10]. Young children are particularly vulnerable to bacterial meningitis, possibly due to 
immaturity of their immune systems, and also have poorer outcomes [10]. To assess the 
extent of sequelae a long term retrospective study of children treated for bacterial meningitis 
was undertaken in the 1980’s in the United States, which reported that 8.5% of children 
surviving bacterial meningitis had major neurological deficits (e.g. mental retardation, 
seizures, hydrocephalus, cerebral palsy, blindness, hearing loss), and 18.5% had learning 
difficulties and developmental problems which persisted up to 12 years after the initial 
episode [2]. The same neurological sequelae were evident in a literature review on bacterial 
meningitis in African children [10].  
Human immunodeficiency virus (HIV) infection is a major risk factor for IPD due to 
impairment of both cell mediated and humoral immunity. The introduction of antiretroviral 
therapy (ART) in South Africa in 2004 caused a marked reduction in the incidence of IPD in 
HIV-infected children. In Gauteng Province, the overall estimated coverage with ART in 
HIV-infected children requiring treatment increased from 21.5% in 2004 to 83.4% in 2009 
[11]. However, even in the era of ART management of HIV-infected children, they remain at 
a 20-fold greater risk for IPD compared to the general population [12]. The efficacy of PCV 
in preventing IPD in HIV-infected children was observed to be 53% compared to 42% in 
HIV-uninfected children [13]. 
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1.2 Vaccine Review 
In February 2000, a 7-valent PCV (PCV7:Prevenar®, Wyeth Lederle Vaccines) was licensed 
by the Food and Drug Administration for use among infants and young children in the United 
States [7]. In 2007, the WHO recommended that all countries include PCVs in their national 
immunization schedules [4].  A systematic review of pre- and post-licensure data did not 
identify major safety problems with PCV7 or other PCV formulations [7]. 
Although there are 93 different pneumococcal serotypes, the serotypes included in PCV7 are 
those most commonly found to cause IPD, namely serotypes 4, 6B, 9V, 14, 18C, 19F, 23. 
These are collectively responsible for 58-66% of all IPD worldwide [14]. 70% of IPD cases 
in children under the age of 5 years in South Africa are due to the serotypes contained in 
PCV7. PCV13 extends this cover, by including six additional serotypes (1, 3, 5, 6A, 7F, 
19A). In the pre-vaccine era, pneumococcal serotypes included in PCV13 were responsible 
for approximately 85% of under-5 IPD episodes in South Africa [15]. 
In 2009, the Cochrane Collaboration undertook a systematic review of PCV randomised 
controlled trials to evaluate the efficacy of PCVs against IPD and pneumonia in both 
industrialised and developing countries. They concluded these vaccines to be efficacious in 
protecting against vaccine-serotype specific IPD [16]. 
Studies in the United States have reported marked reductions in the incidence of IPD and 
pneumococcal meningitis following the introduction of PCV7. This reduction is not only 
through the direct protection of immunised children, but also by protecting non-immunised 
children and adults through an indirect (or ‘herd’) effect, resulting from interruption of 
transmission of vaccine-serotype pneumococci from immunised young children to other non-
immunised individuals [1]. In 2001, the rate of IPD among children under 2 years of age was 
69% lower than in 1998 and 1999 in the United States [17] and the incidence of 
4 
 
pneumococcal meningitis in children <2years of age decreased by 64% between these periods 
[1]. 
Prevenar® was included in the South African Expanded Programme on Immunization (EPI) 
in 2009 and was available since April 2009 in Gauteng Province. Although the vaccine is 
registered for a three dose primary series and booster dose in the second year of life, the 
schedule adopted in the South African EPI was three doses: two primary doses at 6 weeks, 14 
weeks and a third dose at 9 months of age. This was done to address in part the waning 
immunity against IPD which had been observed previously in HIV-infected children when 
only given a three dose primary series at 6, 10 and 14 weeks of age in the absence of a 
booster dose [18]. In mid-2011, PCV13 superseded PCV7 in the South African EPI. 
In the United States in 2006, PCV7 coverage amongst children 19 to 35 months of age was 
estimated to exceed 68% for the full vaccine series of four or more doses, and to exceed 87% 
for three or more doses [1]. The WHO estimated the South African 3
rd
 dose Haemophilus 
influenzae type b vaccine coverage to be around 80% in 2000 [19]. The WHO estimates 1
st
 
dose measles-containing vaccine (MCV1, given at 9 months of age) South African coverage 
rates in 2011 to be 95% in 2011 [20]. It is anticipated that a three dose schedule for PCV7 or 
PCV13 (given at 6 weeks, 14 weeks and 9 months in South Africa) will have coverage of 
>90%. 
The effectiveness of PCV in immunization programs has exceeded expectations compared to 
what was observed in efficacy trials [13]. This may be partially due to the indirect effect of 
childhood PCV immunization. It is anticipated that the inclusion of PCV7 and PCV13 into 
the South African EPI will have resulted in appreciable declines in IPD, including meningitis 
caused by vaccine-serotype specific pneumococci, in children in South Africa. 
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1.3 Hypothesis and Objectives 
Null Hypothesis 
The introduction of PCV into the South African EPI schedule and Gauteng in April 2009 will 
not have changed the epidemiology of bacterial meningitis in children residing in Soweto. 
Primary Objective 
To analyse the impact which the introduction of PCV  in the South African EPI has had on 
confirmed pneumococcal meningitis in children under 1 year of age in Soweto. 
Secondary Objectives 
 To analyse the impact which PCV has had on the incidence of confirmed 
pneumococcal and suspected bacterial meningitis in children less than 14 years of age 
in Soweto. 
 To analyse the impact which PCV has had on the epidemiology of non-pneumococcal 
culture-confirmed bacterial meningitis in children less than 14 years of age in Soweto. 
 
 
 
 
 
6 
 
2. 0 Methods 
2.1 Study Population 
Chris Hani Baragwanath Academic Hospital (CHBAH) is the only public sector hospital in 
Soweto, and serves approximately 1.1 million, mainly black urban, South Africans. This 
includes 120,000 children under five years of age [21]. An estimated 90% of individuals in 
Soweto requiring hospitalisation are admitted to CHBAH, as less than 10% of the population 
has medical insurance [11]. Paediatric admissions to CHBAH over the study period (2006-
2010) average around 7,000 patients per year (CHBAH Department of Paediatrics ward 
statistics). 
 
2.2 Meningitis diagnosis at CHBAH 
Children (< 14 years of age) with suspected meningitis who present to CHBAH have a 
lumbar puncture performed to aid in diagnosis as standard-of-care. Being a secondary/tertiary 
care academic hospital, there is a low threshold for performing lumbar punctures in children, 
including any child with symptoms and signs of meningism as well as a first episode of 
febrile convulsions. 
Paper-based discharge summaries, which detail the cause and course of hospitalisation in 
children requiring admission to the general paediatric wards at CHBAH, are entered into an 
electronic Paediatric Database, with discharge diagnoses coded using the ICD-10 coding 
system. All discharge summaries dating back to 2006 were coded for diagnoses by two 
medical doctors. The electronic Paediatric Database is maintained and updated at the 
Respiratory & Meningeal Pathogens Research Unit (RMPRU) at CHBAH. The completeness 
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of the paper-based discharge summaries were cross-validated against ward registries of the 
general paediatric medical wards as well as the acute-care admissions ward at CHBAH, 
where all admitted  children  are registered. For subjects with missing discharge summary 
records, information available from the ward registries which include date of admission, 
age/date of birth, admission and discharge diagnosis and outcome were summarised and also 
coded using ICD-10. 
 
All cerebrospinal fluid (CSF) and blood samples from patients at CHBAH are sent to the 
National Health Laboratory Service (NHLS) laboratory on site. CSF samples are routinely 
divided into aliquots for cell counts, chemistry and microbiologic testing. If the sample is 
insufficient, CSF samples are prioritised for visualisation of bacterial organisms with a Gram 
stain and inoculation of serum broth and agar plates. Second priority is cell count and 
biochemistry and last is bacterial antigen detection testing using latex agglutination assays. 
The cell count is done manually using a Fuchs-Rosenthal counting chamber with all 
polymorphonuclear cells, lymphocytes and red cells recorded per cubic millimetre. A Giemsa 
stain is performed if the total white cell count is greater than 100 or if there is difficulty 
differentiating between polymorphonuclear cells and lymphocytes. 
For the culture of specimens, depending on the volume of sample received, the sample is 
either centrifuged or, if less than 1ml received, put in a vortex mixer. The sediment (bacteria 
and cells) is used to inoculate the culture media. Culture media used include brain-heart 
infusion (BHI) broth, blood agar and chocolate agar. All plates are examined daily, for 
macroscopic evidence of growth up until 72 hours post-inoculation. If bacterial growth is 
identified, a Gram stain is performed to identify the organism. Pure cultures of organisms 
isolated from CSF specimens are prepared, and susceptibility to antimicrobial agents is 
determined using disc diffusion methods and (for pneumococcus), E-tests. 
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Latex agglutination tests are only done if requested by the clinician who submitted the 
specimen. The NHLS lab uses the Wellcogen Bacterial Antigen Kit (Wellcome Diagnostics: 
Product number R30859001, ZL22). The kit provides reagents for the detection of bacterial 
antigens of H. influenzae type b, Streptococcus agalactiae, S. pneumoniae, Neisseria 
meningitidis A, C, Y and W135, N. meningitidis B and Escherichia coli K1. The CSF 
specimen is mixed with latex reagent on a slide and if positive, agglutination will develop 
within 3 minutes. Positive and negative controls are performed at the same time for quality 
control purposes.  
For requested blood cultures the NHLS lab uses Paediatric BactT/ALERT bottles 
(Biomerieux: Reference 259794). Isolated pathogens are identified and susceptibility patterns 
determined using standard laboratory techniques. 
 
2.3 Study Method 
All children <14 years of age admitted to CHBAH with confirmed or suspected meningitis 
from 01 January 2006 until 31 December 2010 were identified by searching against the 
electronic Paediatric Database using the appropriate ICD 10 codes (Appendix 1, page 33). 
Patients identified as having been admitted with confirmed or suspected meningitis during the 
period under investigation were cross-referenced against the database of the National Health 
Laboratory Service (NHLS) to identify those children who had meningitis as per the study 
definitions.  
For the purposes of this study, case definitions for bacterial meningitis were as follows: 
 Confirmed bacterial meningitis: culture-confirmed bacterial meningitis, 
regardless of pathogen isolated; 
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 Probable bacterial meningitis: CSF cultures negative with presence of 
surrogate indicators of bacterial meningitis on baseline investigation. 
Surrogate indicators of bacterial meningitis included: CSF white cell count of 
>100 cells/mm
3
and at least a protein of >1.0g/l or glucose of <2.2mmol/l [19]. 
 Cases of tuberculosis meningitis were excluded. 
For those patients who met the study case definitions of bacterial meningitis (TB meningitis 
excluded), data as enumerated in Appendix 2 (page 34) was extracted from the NHLS 
database. 
 HIV infection status of children identified as having meningitis was attributed as follows:  
 HIV enzyme-linked immunosorbent assay (ELISA) positive in a child over 18 
months of age: HIV-infected; 
 HIV ELISA positive in a child under 18 months of age, with positive HIV 
polymerase chain reaction (PCR): HIV-infected; 
 HIV ELISA positive in a child under 18 months of age, with negative HIV 
PCR: HIV exposed, uninfected; 
 HIV ELISA positive in a child under 18 months of age, with no HIV PCR: 
HIV-exposed but status indeterminate; 
 No HIV test available, regardless of age group: HIV status undetermined. 
For the evaluation of increasing access of the paediatric population to ART as a potential 
contributor to declining meningitis incidence in HIV-infected children, time periods were 
stratified according to the coverage of ART within the community as previously reported: 
2006 being the intermediate ART era (51% ART coverage for HIV-infected children with 
AIDS) and 2007 onwards being the established ART era (>74% ART coverage in HIV-
infected children eligible for treatment per national guidelines) [12]. 
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To assess the impact that PCV has had on the population most at risk, and who would have 
benefitted most from the vaccine during the study time frame, the age group under 1 year of 
age was specifically looked at with the population stratified into <1year and >1year age 
groups. 
 
2.4 Statistical Analysis 
The numerators for bacterial meningitis incidence calculation were the number of meningitis 
cases identified in each year, and the population denominators were based on mid-year 
population estimates from the Gauteng Department of Health and Social Development for 
region D (Soweto) in Johannesburg as per Statistics South Africa report [21], shown in 
Appendix 3 (page 35).  
The HIV prevalence in the study population was estimated from the projections of the AIDS 
and Demographic models developed by the Actuarial Society of South Africa [21] and 
tabulated in Appendix 4 (page 36). 
Unadjusted data were quoted in the results. However, to account for those cases with an 
unknown HIV result, we extrapolated our data to include these cases. In this sensitivity 
analysis, children with unknown HIV status were assigned as being either HIV-infected or 
HIV-uninfected based on the proportional percentage of known results in the HIV tested 
group.  
X
2 
Test (or Fisher’s exact test) were used to compare the distribution of categorical variables, 
and 95% confidence intervals are reported with p-values <0.05 considered as being 
statistically significant. Demographic data and estimates of incidence and risk ratio were 
analysed using STATA version 11.0 (StataCorp, College Station, Texas). 
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A Poisson regression model with terms for quarter and cyclical terms were fitted to the data. 
To then compare the pre-PCV and post-PCV time periods an additional indicator variable for 
the period post-vaccine was included. This allowed comparison of the incidence in the two 
groups and rate ratio calculation. 
 
2.5 Study approval 
Permission to conduct the study at CHBAH was obtained from the Medical Advisory 
Committee at the hospital and also from the NHLS for access to electronic data and 
laboratory records.  
Ethics approval was granted by the Human Research Ethics Committee (HREC), University 
of Witwatersrand (HREC number: M111176), who granted a waiver for patient consent due 
to this being a retrospective review of medical records. 
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3.0 Results 
 
3.1 Overall meningitis 
Seven hundred and eighty three children were admitted with suspected meningitis from 
January 2006 to December 2010, with a male-to-female ratio of 1.55:1. Of the 783 cases, 243 
(31%) met the study criteria for bacterial meningitis, among whom the male-to-female ratio 
was 1.36:1. The median age of the children who met the study criteria was 8.8 months 
(Interquartile Range [IQR], 0 – 159.4 months). 
Of the 243 with bacterial meningitis, 116 (48%) were HIV-uninfected, 82 (34%) were HIV-
infected, and 45 (18%) had undetermined HIV status. 
Table 1: Demographic data of children with meningitis 
 Suspected meningitis Bacterial meningitis 
Total 783 243 
Age 
Mean (months) 
Median (months) 
 
36.3 (SD 45.8 months) 
13.6 (IQR 3.0 – 58.8 months) 
 
32.0  (SD 43.6 months) 
8.8. (IQR 0 – 159.4 months) 
Gender 
Male 
Female 
 
476 (61%) 
307 (39%) 
 
140 (58%) 
103 (42%) 
HIV Status 
HIV-uninfected 
HIV-infected 
HIV status undetermined 
 
508 (65%) 
159 (20%) 
116 (15%) 
 
116 (48%) 
82 (34%) 
45 (18%) 
13 
 
Culture-positive CSF findings are tabulated in Table 2. This identified that S. pneumoniae 
contributed towards 55% of all culture-confirmed meningitis cases in the 5-year period. 
The observed change in incidence for the different bacterial meningitis pathogens is plotted 
in Figure 1. The graph shows a rapid decline in pneumococcal meningitis from 2009 and does 
not show any marked variation in the incidence of the other meningitis pathogens over the 
years. 
Table 2: The number of cases of all bacterial meningitis pathogens during the study period. 
 2006 
N (%) 
2007 
N (%) 
2008 
N (%) 
2009 
N (%) 
2010 
N (%) 
Total 
N (%) 
Streptococcus 
pneumonia 
42 (55) 30 (60) 31 (63.3) 21(50) 10 (40) 134(55.1) 
Bacteria 
unspecified 
6 (8) 5 (10) 5 (10.2) 8 (19) 3 (12) 27 (11.1) 
Escherichia coli 1 (1) 0 (0) 0 (0) 1 (2.4) 4 (16) 6 (2.5) 
Neisseria 
meningitides 
7 (9) 1 (2) 0 (0) 1 (2.4) 1 (4) 10 (4.1) 
Haemophilus 
influenza 
6 (8) 5 (10) 3 (6.1) 6 (14.3) 3 (12) 23 (9.5) 
Streptococcus 
agalactiae 
11 (14) 8 (16) 8 (16.3) 1 (2.4) 3 (12) 31 (12.7) 
Other* 4 (5) 1 (2) 2 (4.1) 4 (9.5) 1 (4) 12 (5) 
TOTAL CASES 77 (100) 50 (100) 49 (100) 42 (100) 25 (100) 243 (100) 
 
* Of other: Acinetobacter baumannii (one case in 2006), Klebsiella spp (two cases in 2009), Salmonella spp 
(one case each in 2006, 2007 and 2009), Staphylococcus aureus (one case in 2010), Streptococcus spp (two 
cases in 2006, two cases in 2008). 
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Figure 1: Annual incidence of meningitis per 100,000 stratified by meningitis type. 
 
 
Trends in incidence of all bacterial meningitis 
To analyse the impact that the introduction of PCV had on all bacterial meningitis the number 
of cases of meningitis according to the study definition were divided into annual quarters for 
all age groups (Table 3) and for children under 1 year of age (Table 4). The highlighted 
column in the tables indicates the time of introduction of the PCV. Using the Soweto region 
population figures as the denominator, the incidence was calculated and a regression model 
with a term for pre-vaccine (before the second quarter of 2009) or post-vaccine (from the 
second quarter of 2009, onwards) was generated.
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Table 3: Bacterial meningitis by annual quarters in all ages: 
Year 
 
2006 2007 2008 2009 2010 
Quarter 
 
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
All bacterial 
meningitis 
17 21 22 17 12 17 13 8 9 14 17 9 15 7 15 5 10 4 3 8 
Pneumococcal 
meningitis 
8 14 11 9 4 12 9 5 6 10 9 6 5 6 6 4 4 1 2 3 
Other 9 7 11 8 8 5 4 3 3 4 8 3 10 1 9 1 6 3 1 5 
 
 
Table 4: Bacterial meningitis by annual quarters in children <1 year of age: 
Year 2006 2007 2008 2009 2010 
Quarter 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
All bacterial 
meningitis 
7 10 14 9 9 7 9 3 5 11 10 6 10 3 11 0 7 4 1 3 
Pneumococcal 
meningitis 
3 5 8 5 2 5 6  2 7 7 4 2 3 5 0 1 1 0 0 
Other 4 5 6 4 7 2 3 2 3 4 3 2 8 0 6 0 6 3 1 3 
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The rate ratio of all meningitis between consecutive months was 0.953 for all children before 
2009 (Table 5) indicating that, even prior to inclusion of PCV into the South African EPI 
there was a decline of 4.7% per annum in culture-confirmed bacterial meningitis amongst 
children being admitted to CHBAH. After 2009 the rate ratio declined further to 0.895 
(10.5% per annum), however, this rate of decline between the pre- and post-PCV periods was 
not statistically significant; P=0.391. This change in reduction is graphically represented in 
Figure 2. 
 
Table 5: Regression Model for all meningitis pre and post vaccine introduction in all age 
groups 
 
 Estimate Std Error z value Pr (>|z|) 
Intercept 1.81 0.144 12.567 0.000 
Time -0.048 0.019 -2.449 0.014 
Pre 0.811 1.183 0.685 0.493 
Time:pre -0.063 0.073 -0.859 0.391 
 
 
 
 
 
 
 
 
 
 
 
17 
 
Figure 2: Regression model for all bacterial meningitis in all age groups 
 
 
 
 
The same regression model was used to analyse the effect of PCV immunization in children 
less than one year of age, the results of which were tabulated (Table 6). In this age-group, the 
rate ratio of all meningitis between consecutive months was 0.99 before 2009. After 2009 this 
changed to 0.857. This indicates that the incidence of meningitis was decreasing by 1% year-
on-year in the pre-PCV era, while the decline accelerated to 14.3% year-on-year in the post-
PCV era; P=0.145. This change is graphically represented in Figure 3. 
 
 
 
 
The thick black line is the number of observed culture-confirmed bacterial meningitis cases.  
The solid grey line is the predicted number of cases when fitting the model to just the data from 
2006-2009 (i.e., removing the effect of PCV on meningitis incidence trends).  
The dashed grey lines are the prediction intervals for the predicted values. 
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Table 6: Regression Model for all meningitis pre and post vaccine introduction in children <1 
year of age. 
 
 Estimate Std Error z value Pr (>|z|) 
Intercept 3.738 0.197 18.994 0.000 
Time -0.010 0.025 -0.403 0.687 
Pre 1.757 1.590 1.105 0.269 
Time:pre -0.144 0.099 -1.458 0.145 
 
 
 
Figure 3: Regression model for all bacterial meningitis in children <1 year of age 
 
 
 
 
 
 
The thick black line is the number of observed culture-confirmed bacterial meningitis cases.  
The solid grey line is the predicted number of cases when fitting the model to just the data from 
2006-2009 (i.e., removing the effect of PCV on meningitis incidence trends).  
The dashed grey lines are the prediction intervals for the predicted values. 
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3.2 Pneumococcal Meningitis 
Trends in incidence of Pneumococcal meningitis in all age groups 
Data from (Table 3) was used to infer the impact which the introduction of PCV has had on 
the incidence of pneumococcal meningitis, by applying a regression model with a term for 
pre-vaccine or post-vaccine.  
The results of the regression model are represented in Table 7 and show the rate ratio of all 
meningitis between consecutive months was 0.953 for all children before 2009. After 2009 
this changed to 0.817. This means that the incidence was decreasing by 4.7% prior to the 
vaccine being introduced and post introduction this decrease accelerated to 18%, albeit also 
not statistically significant, P=0.146. This change is graphically represented in Figure 4. 
 
Table 7: Regression Model for pneumococcal meningitis pre and post vaccine introduction in 
all age groups 
 
 Estimate Std Error z value Pr (>|z|) 
Intercept 1.242 0.191 6.485 0.000 
Time -0.048 0.026 -1.852 0.064 
Pre 2.192 1.692 1.295 0.195 
Time:pre -0.154 0.106 -1.453 0.146 
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Fig 4: Regression model for pneumococcal meningitis in all age groups 
 
 
 
 
 
 
 
 
 
 
The temporal association of PCV immunization on the incidence of pneumococcal meningitis 
in children less the one year of age is shown in Table 4, which was applied to a regression 
model graph with a term for pre-vaccine or post-vaccine. This age group was specifically 
looked at, as this is the population most at risk of IPD and would have received the maximum 
benefit of the PCV immunization program, in the absence of a catch-up campaign of 
vaccination of older children. The results of the regression model are depicted in Table 8 and 
show the rate ratio of all meningitis between consecutive months was 0.989 for all children 
before 2009. After 2009 this changed to 0.566. This indicates that the incidence was 
decreasing by 1.1% in the pre-vaccine era, which accelerated to a 43.4% year-on-year decline 
post PCV introduction, P=0.011. Pneumococcal meningitis incidence trends in children less 
than one year of age are graphically represented in Figure 5. 
The thick black line is the number of observed pneumococcal meningitis cases.  
The solid grey line is the predicted number of pneumococcal meningitis cases when fitting the 
model to just the data from 2006-2009 (i.e., removing the effect of PCV on pneumococcal 
meningitis incidence trends).  
The dashed grey lines are the prediction intervals for the predicted values. 
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Table 8: Regression Model for pneumococcal meningitis pre and post vaccine introduction 
children <1 year of age 
 
 Estimate Std Error z value Pr (>|z|) 
Intercept 3.086 0.273 11.297 0.000 
Time -0.011 0.035 -0.310 0.757 
Pre 7.886 3.326 2.371 0.018 
Time:pre -0.558 0.220 -2.537 0.011 
 
 
Fig 5: Regression model for pneumococcal meningitis in children <1 year of age 
 
 
 
 
The thick black line is the number of observed pneumococcal meningitis cases.  
The solid grey line is the predicted number of pneumococcal meningitis cases when fitting the 
model to just the data from 2006-2009 (i.e., removing the effect of PCV on pneumococcal 
meningitis incidence trends).  
The dashed grey lines are the prediction intervals for the predicted values. 
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3.3 Trends in the HIV-infected population 
Previous studies have shown a reduction in IPD in HIV-infected children following 
increasing usage of ART. The periods 2006 and 2007-2010 were defined as intermediate and 
established ART access eras, respectively. By comparing the incidence of pneumococcal 
meningitis in the two periods we were able to assess the impact improved ART access had on 
pneumococcal meningitis. To assess the impact that PCV contributed to the decline in the 
established era, we split the established ART era into two time periods 2007-2008 and 2009-
2010 (without and with PCV availability respectively). 
To calculate the incidence of pneumococcal meningitis in the study population the study 
results were stratified according to age and HIV status (Table 9).  
To assess the impact that the up-scaling of the ART program had on the incidence of 
pneumococcal meningitis in HIV-infected children, the two eras (excluding the years in 
which the vaccine was available) were compared using Chi squared trends (Table 10). The 
incidence declined from 219 per 100,000 in the intermediate era to 152 per 100,000 in the 
established era, a 30% reduction in incidence (95%CI: -22.1-60.3%; P=0.20). 
The combined effect that PCV and up-scaled ART access had on pneumococcal meningitis in 
HIV-infected children is depicted in Table 11. The incidence of pneumococcal meningitis in 
the HIV-infected population declined from 219 per 100,000 to 108 per 100,000, i.e. a 49.4% 
reduction (95%CI: 29.2-83.3%; P=0.02) and was greater than the reduction caused by 
increased ART access alone. Although there was an overlap in the confidence intervals of the 
two groups, the reduction was only significant in the combined ART and PCV group. 
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Sensitivity Analysis: All Age Groups 
The sensitivity analysis (Tables 10 and 11) showed pneumococcal meningitis incidence 
amongst HIV-infected children in the years excluding vaccine availability was 296 per 
100,000 in the intermediate era and 167 per 100,000 in the established era, a 43% reduction 
in incidence (95%CI: 6.2-65.8%; P=0.02). When including the years that PCV was available 
in the established era, the incidence dropped further from 167 per 100,000 to 119 per 
100,000, a 40% reduction (95%CI: 25.5-64.4%; P=0.0001) which was significant, but not 
different to the impact seen from up-scaling of ART alone. 
 
Pneumococcal Meningitis Incidence Trends in HIV–infected Infants 
As was observed in the analysis of all meningitis and pneumococcal meningitis incidence 
trends regardless of HIV infection status, the maximum benefit of PCV immunization 
amongst HIV-infected children was in infants. We therefore analysed this specific age group 
(less than one year of age) to determine the impact of increased ART compared to increased 
ART with PCV coverage (Tables 12 and 13). In the intermediate ART era the incidence of 
pneumococcal meningitis was 531 per 100,000. In the established ART era, when the vaccine 
was not available, pneumococcal meningitis incidence in HIV-infected children less than one 
year of age declined to 371 per 100,000. This showed a 30% reduction due to increased ART 
access (95%CI: -10.1-75.6%; P=0.51). When the years that PCV was available were 
included, the incidence in the established ART era decreased further to 220 per 100,000, 
showing a 58% reduction (95%CI: -14.5-84.8; P=0.079). 
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Sensitivity Analysis: Children Less Than One Year of Age 
To again account for the cases with an unknown HIV result in the less than one year age 
group, we conducted a sensitivity analysis as described previously. Prior to the introduction 
of the vaccine (Tables 12 and 13) the incidence of pneumococcal meningitis was 796 per 
100,000 in the intermediate ART era, and 418 per 100,000 in the established ART era. This 
represents a 47% reduction (95%CI: -32.4-79%; P=0.52). In the comparison including the 
years in which PCV was available, the incidence in the established ART era reduced further 
to 264 per 100,000, i.e. a reduction of 67% (95%CI: 20.9-85.9%; P=0.0089) which was 
greater than the reduction obtained from simply up-scaling ART. 
 
 
Table 9: Number of cases of pneumococcal meningitis stratified by age and HIV status 
 2006 2007 2008 2009 2010 
+ - ? Total + - ? Total + - ? Total + - ? Total + - ? Total 
<1 6 8 7 21 4 7 3 14 4 14 2 20 2 5 3 10  2  2 
1-2 8   3 4 1  5 1 2 1 4  1  1 3   3 
2-5 2 2 1 5 4   4    0 2 1  3 1 1  2 
5-14 9 1 3 13 7   7 7   7 6 1  7 2 1  3 
Total 20 11 11 42 19 8 3 30 12 16 3 31 10 8 3 21 6 4  10 
HIV Status 
+ = HIV-infected 
- = HIV-uninfected 
? = HIV status undetermined 
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Table 10: Incidence of pneumococcal meningitis in children <14yrs in the Intermediate and 
Established ART eras prior to vaccine introduction  
 Intermediate-ART 
2006 
Incidence of pneumococcal 
meningitis 1 
[95%CI] 
(N of pneumococcal cases) 
Established-ART 
2007-2008 
Incidence of pneumococcal 
meningitis 1 
[95%CI] 
(N of pneumococcal cases) 
IRR
2 
P-
value
3 
% reduction
4 
Total 12.2 [8.8-16.5] 
(42) 
8.6 [6.6-11] 
(61) 
0.7 
[0.48-1.05] 
0.08 29.4 
[-4.5-52.4] 
HIV-infected 219.1 [133.9-338.2] 
(20) 
152.5 [103.6-216.4] 
(31) 
0.69 
[0.39-1.22] 
0.2 30.3 
[-22.1-60.3] 
HIV-uninfected 3.3 [1.6-5.9] 
(11) 
3.5 [2.2-5.2] 
(24) 
1.1 
[0.52-2.17] 
0.87 Not applicable 
HIV-infected EX
5 295.8 [195-430] 
(27) 
167.3 [115.9-233.7] 
(34) 
0.57 
[0.34-0.94] 
0.02 43.4 
[6.2-65.8] 
HIV-uninfected 
EX
6 
4.5 [2.5-7.4] 
(15) 
3.9 [2.6-5.7] 
(27) 
0.88 
[0.47-1.65] 
0.68 12.3 
[-64.8-53.4] 
 
1
Number of cases per 100,000 
2
Incidence risk ratios – Intermediate vs. Early ART era 
3
 X
2
 test or Fisher exact test 
4
 % reduction between Intermediate and Established ART era  
5 
Incidence of pneumococcal meningitis in HIV-infected children extrapolated proportionally to include HIV 
unknown 
6
Incidence of pneumococcal meningitis in HIV-uninfected children extrapolated proportionally to include HIV 
unknown 
 
 
Table 11: Incidence of pneumococcal meningitis in children <14yrs in the Intermediate and 
Established ART eras including years after vaccine introduction 
 Intermediate-ART 
2006 
Incidence of pneumococcal 
meningitis 1 
[95%CI] 
(N of pneumococcal cases) 
Established-ART 
2007-2010 
Incidence of pneumococcal 
meningitis 1 
[95%CI] 
(N of pneumococcal cases) 
IRR
2 
P-
value
3 
% reduction
4 
Total 12.2 [8.8-16.5] 
(42) 
6.4 [5.1-7.8] 
(92) 
0.5 
[0.36-0.75] 
0.0004 47.7 
[24.7-63.7] 
HIV-infected 219.1 [133.9-338.2] 
(20) 
108 [79.4-143.6] 
(47) 
0.49 
[0.29-0.83] 
0.0069 49.4 
[29.2-83.3] 
HIV-uninfected 3.3 [1.6-5.9] 
(11) 
2.6 [1.8-3.6] 
(36) 
0.78 
[0.4-1.5] 
0.478 21.7 
[-53.9-60.1] 
HIV-infected EX
5 295.8 [195-430] 
(27) 
119.5 [89.3-156.7] 
(52) 
0.4 
[0.25-0.64] 
0.0001 40.5 
[25.5-64.4] 
HIV-uninfected 
EX
6 
4.5 [2.5-7.4] 
(15) 
2.9 [2-3.9] 
(40) 
0.64 
[0.35-1.16] 
0.135 36.1 
[-15.6-64.7] 
 
1
Number of cases per 100,000 
2
Incidence risk ratios – Intermediate vs. Early ART era 
3
 X
2
 test or Fisher exact test 
4
 % reduction between Intermediate and Established ART era  
5 
Incidence of pneumococcal meningitis in HIV-infected children extrapolated proportionally to include HIV 
unknown 
6
Incidence of pneumococcal meningitis in HIV-uninfected children extrapolated proportionally to include HIV 
unknown 
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Table 12: Incidence of pneumococcal meningitis in children <1yr in the Intermediate and Established 
ART eras including years prior to vaccine introduction  
 Intermediate-ART 
2006 
Incidence of pneumococcal 
meningitis 1 
[95%CI] 
(N of pneumococcal cases) 
Established-ART 
2007-2008 
Incidence of pneumococcal 
meningitis 1 
[95%CI] 
(N of pneumococcal cases) 
IRR
2 
P-
value
3 
% reduction
4 
Total 93.8 [58-143.4] 
(21) 
80 [55.5-112] 
(34) 
0.85 
[0.49-1.47] 
0.57 14.5 
[-47.2-50.3] 
HIV-infected 531 [195-1152] 
(6) 
371 [160-731] 
(8) 
0.7 
[0.24-2] 
0.51 29.9 
[-10.1-75.6] 
HIV-uninfected 37.6 [16.2-74.2] 
(8) 
52.2 [32-79.7] 
(21) 
1.4 
[0.6-3.2] 
0.41  
HIV-infected EX
5 796 [364.8-1506.5] 
(9) 
418.2 [191.4-792.4] 
(9) 
0.52 
[0.21-1.12] 
0.169 47.2 
[-32.4-79] 
HIV-uninfected 
EX
6 
56.4 [29.2-98.6] 
(12) 
62.1 [40.2-91.7] 
(25) 
1.1 
[0.55-2.19] 
0.78  
 
1
Number of cases per 100,000 
2
Incidence risk ratios – Intermediate vs. Early ART era 
3
 X
2
 test or Fisher test 
4
 % reduction between Intermediate and Established ART era  
5 
Incidence of pneumococcal meningitis in HIV-infected children extrapolated proportionally to include HIV 
unknown 
6
Incidence of pneumococcal meningitis in HIV-uninfected children extrapolated proportionally to include HIV 
unknown 
 
 
Table 13: Incidence of pneumococcal meningitis in children <1yr in the Intermediate and Established 
ART eras including years after vaccine introduction  
 Intermediate-ART 
2006 
Incidence of pneumococcal 
meningitis 1 
[95%CI] 
(N of pneumococcal cases) 
Established-ART 
2007-2010 
Incidence of pneumococcal 
meningitis 1 
[95%CI] 
(N of pneumococcal cases) 
IRR
2 
P-
value
3 
% reduction
4 
Total 93.8 [58-149.4] 
(21) 
52.8 [38.7-70.5] 
(46) 
0.56 
[0.34-0.94] 
0.027 43.6 
[5.6-66] 
HIV-infected 531 [195-1152] 
(6) 
220.7 [105.9-405.5] 
(47) 
0.42 
[0.15-1.14] 
0.079 58.3 
[-14.5-84.8] 
HIV-uninfected  37.6 [16.2-74.2] 
(8) 
33.9 [22.5-49] 
(28) 
0.9 
[0.41-1.98] 
0.79 9.8 
[-97.8-58.9] 
HIV-infected  EX
5 796 [364.8-1506.5] 
(9) 
264.8 [136.9-462.2] 
(12) 
0.33 
[0.14-0.79] 
0.0089 66.6 
[20.9-85.9] 
HIV-uninfected 
EX
6 
56.4 [29.2-98.6] 
(12) 
41.2 [28.5-57.6] 
(34) 
0.73 
[0.38-1.41] 
0.346 27 
[-40.9-62.2] 
 
1
Number of cases per 100,000 
2
Incidence risk ratios – Intermediate vs. Early ART era 
3
 X
2
 test or Fisher test 
4
 % reduction between Intermediate and Established ART era  
5 
Incidence of pneumococcal meningitis in HIV-infected children extrapolated proportionally to include HIV 
unknown 
6
Incidence of pneumococcal meningitis in HIV-uninfected children extrapolated proportionally to include HIV 
unknown 
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4.0 Discussion 
The introduction of PCV into the South African immunization program was temporally 
associated with a decrease in incidence of pneumococcal meningitis in both HIV-infected and 
HIV-uninfected children. This reduction was greatest in children less than one year of age 
who have been specifically targeted for immunization since May 2009. 
The incidence of pneumococcal meningitis was decreasing in the paediatric population of 
children admitted to CHBAH by 4.7% per annum prior to the introduction of PCV, and this 
decline was accelerated to 18% per annum following PCV introduction. The decreasing 
pneumococcal incidence rates observed in the era of access to PCV did not reach statistical 
significance in our analysis. 
The population at highest risk of invasive pneumococcal disease in our setting are infants 
under one year of age [5], which was also the age-group specifically targeted for PCV 
immunization (three doses, given at six and fourteen weeks, and nine months of age) and who 
stand to benefit from the direct effect of the vaccine, as there had not been any catch-up 
campaign for older children until 2011. In the under-one year age-group there was a 
statistically significant decline in the incidence of pneumococcal meningitis (from 1.1% per 
annum prior to PCV introduction, to 43.4% after the introduction of PCV). This PCV-related 
decline in the incidence of hospitalisation for confirmed pneumococcal meningitis occurred 
in the context, and accelerated, a secular decline in meningitis incidence which was occurring 
prior to vaccine introduction (Figure 1). 
A study in the United States showed a decline in pneumococcal meningitis of 64% in 
children under two years of age, four years after the introduction of pneumococcal vaccine 
[1]. However this time period included a catch-up campaign and the predicted serotype 
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coverage (of PCV7) in the United States is 85% compared to 55-60% in South Africa [14]. 
Our study only looked at the impact of PCV in the immediate 21 months period following its 
introduction, and yet demonstrated a statistically significant vaccine effect in children less 
than one year of age.  
There is a theoretical concern that with the reduction of one meningitis type (e.g. 
pneumococcal meningitis) there will be an increase in other types of meningitis attributed to 
bacterial species that were not as prevalent in the pre-vaccine era. When looking at the 
incidence of all meningitis, there was a persistent decline in the total incidence of meningitis 
pre- and post-introduction of the vaccine. This was to be expected as pneumococcal 
meningitis contributed over 50% of all confirmed bacterial meningitis cases in the period 
prior to PCV introduction. The numbers of non-pneumococcal meningitis where 
unfortunately too small to do a statistical time series analysis for each pathogen, however, a 
graphical representation showed the incidence to be declining in most cases when comparing 
2006 to 2010 (Figure 1).  
In light of the high burden of HIV in the South African population, we assessed the impact 
that up-scaled delivery of ART had on pneumococcal meningitis incidence and whether this 
impact was a greater contribution to the decline in incidence of pneumococcal meningitis in 
the HIV population than that of PCV.  
The first statistical analysis interrogated the incidence of pneumococcal meningitis in the 
HIV-infected population in the intermediate ART era (2006) compared to disease incidence 
in the established ART era (2007-2010).   
Analysis of the two ART-eras when PCV was not available showed a non-statistical 
significant decline (30%: 95%CI -22.1-60.3%; P=0.20). However the analysis of the two 
ART-eras, including the years that PCV was available, showed a statistically significant 
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reduction (49.4%: 95%CI 29.2-83.3; P=0.02) in the incidence of pneumococcal meningitis. 
This showed that although the ART programs had a significant role in reducing the incidence 
of pneumococcal meningitis in HIV-infected children, this decline accelerated following the 
further introduction of PCV into the EPI. 
Sensitivity analysis conducted by extrapolating the number of unknown HIV results in all 
children proportionally into both HIV-infected and HIV-uninfected groups (based on the 
proportion that was HIV-infected amongst those who were tested for HIV), demonstrated a 
less substantial (43%: 95%CI 6.2-65.8%; P=0.02) but statistically significant difference from 
up-scaling ART alone and a similar reduction in the era with ART combined with PCV 
(40%: 95%CI 25.5-64.4%; P=0.0001). 
As children less than one year of age derived maximum benefit from the vaccine, the effect 
of ART and ART combined with the vaccine was looked at specifically in this population. 
HIV-infected children less than one year showed a reduction of 29.9% (95%CI: -10.1-75.6; 
P=0.51) due to the up-scaled delivery of ART alone. Those children who gained the benefit 
of both up-scaled ART and PCV showed a reduction of 58.3% (95%CI: -14.5-84.8; P=0.079) 
in pneumococcal meningitis. These results indicate that PCV is effective in reducing the 
incidence of pneumococcal meningitis in the HIV-infected population, although the small 
sample size limited our ability to demonstrate statistical significance in these analyses. 
Sensitivity analysis conducted by extrapolating the number of unknown HIV results in those 
children under one year of age proportionally into both HIV-infected and HIV-uninfected 
groups, increased the reduction in the combined ART and PCV group and reached statistical 
significance and the reduction in the combined group was greater, although the confidence 
intervals of the two groups did overlap: 47.2% reduction in the group with only up-scaled 
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ART (95%CI: -32.4-79) compared to a 66.6% (95%CI: 20.9-85.9) reduction in the group 
who received ART and PCV.  
We were able to describe statistically significant outcomes in our analyses, despite the 
necessity to rely on observational and clinical databases from which raw data were obtained. 
Our study has a few limitations. The first limitation of this study is that we used the 
population base as that of Soweto. Although there is only one public sector hospital 
(CHBAH) serving this region, some children may have been admitted elsewhere. 
Furthermore, children not resident in Soweto may have accessed care at CHBAH. However, 
the same population (with likely population flux affecting results throughout the study time 
frame) was looked at pre- and post-PCV implementation and it was the incidence in this 
group that was compared, so this should negate any discrepancy. 
A second limitation is that we were using the paediatric database which has only recently 
been finalised (2011) and may have not completely documented all cases. The possible 
omission of additional confirmed bacterial meningitis cases in our analysis would have 
enhanced our sample size, and may have increased the power of our study to demonstrate 
statistical significance in certain of our analyses. There is no reason to believe that 
deficiencies in data capturing would have affected one time period of the paediatric database 
more than another, so time-trends of an overall reduction of confirmed bacterial meningitis 
cases likely represents the true disease incidence trends. 
The third limitation is that at the time of starting the study the data base was only up to date 
till December 2010. This means that the study interrogated the impact which PCV had in the 
first 21 months after it was introduced into the EPI, and this is not necessarily a true 
reflection of the impact the vaccine will have. In comparison the study done in the United 
States compared the incidence of pneumococcal meningitis prior to the introduction of PCV 
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to the incidence 4 years after its introduction, therefore allowing proper uptake of the vaccine 
into the EPI and the benefit of indirect effect. It is noteworthy that, even in the context of a 
newly implemented preventive strategy (PCV vaccination) where initial coverage may have 
been adversely affected by stock-outs, we were able to demonstrate statistically significant 
vaccine effects on pneumococcal meningitis disease incidence. 
The fourth limitation is the assumption that vaccine coverage would have been similar to that 
of H. influenzae type b conjugate vaccine and that there were no problems encountered in the 
rollout of a new vaccine into the EPI. If the coverage of PCV was low, this would have 
reduced the efficacy of the vaccine and therefore not reflect the full potential of PCV 
immunization. With improved access, delivery and catch-up campaigns there may be a 
greater decline in the incidence of pneumococcal meningitis. 
The fifth limitation of the study is that there were small numbers of cases as we looked at a 
specific hospital population, which limited the power to demonstrate statistical significance.  
A further limitation of the study is that we did not interrogate the pneumococcal serotype data 
for the cases, hence we were unable to demonstrate that the vaccine did not increase the 
incidence of those pneumococcal serotypes not covered in the 7-valent PCV. However this 
was not one of the aims of the study. 
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5.0 Conclusion 
The introduction of PCV was temporally associated with a decline in the incidence of 
pneumococcal meningitis in children.  This decline was most pronounced in infants (i.e. 
children <1 year of age), among whom there was a 1.1% per annum decline prior to PCV-
introduction, which increased to a 43.4% decline post-PCV introduction. 
Improved access to ART was shown to contribute to the decline in the incidence of 
pneumococcal meningitis, however, when combined with PCV the decline was far greater 
than that of up-scaled ART alone. 
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6.0 Appendices 
 
Appendix 1: ICD 10 Codes for Meningitis  
 
ICD-10 Code Description 
A39.0 Meningococcal meningitis 
A87 Viral meningitis 
G02 Meningitis in other infectious and parasitic diseases classified elsewhere 
G03.9 Meningitis unspecified 
G00.0 Haemophilus meningitis 
G00.1 Pneumococcal meningitis 
G00.2 Streptococcal meningitis 
G00.3 Staphylococcal meningitis 
G00.8 Other bacterial meningitis 
G00.9 Bacterial meningitis unspecified 
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Appendix 2: Data extracted from the NHLS System 
 
 Date of specimen submission; 
 CSF findings on admission: white cell count (cells/mm3), protein (g/l), glucose 
(mmol/l), bacterial latex test (if done), Gram stain, bacterial culture, bacterial 
susceptibility test results (including penicillin and cefotaxime minimum 
inhibitory concentrations [MICs]); 
 Blood culture result on admission; 
 Full blood count results on admission: white cell count (cells x 109/l), 
haemoglobin (g/dl), mean cell volume (fl), platelets (x 10
9
/l), and differential 
count (%); 
 C-reactive protein (CRP) on admission (mg/l); 
 HIV status; 
o HIV infection status was attributed as follows:  
1. HIV enzyme linked immunosorbent assay (ELISA) positive in a child 
over 18 months of age: HIV-infected; 
2. HIV ELISA positive in a child under 18 months of age, with positive 
HIV polymerase chain reaction (PCR): HIV-infected; 
3. HIV ELISA positive in a child under 18 months of age, with negative 
HIV PCR: HIV exposed, uninfected; 
4. HIV ELISA positive in a child under 18 months of age, with no HIV 
PCR: HIV-exposed but status indeterminate; 
5. No HIV test available, regardless of age group: HIV status 
undetermined. 
o For HIV-infected children, CD4+ lymphocyte count (absolute [cells x 
10
6
/l], and CD4+ per cent) and HIV viral load (RNA copies/ml) results 
conducted within 2 months of the meningitis  episode were recorded. 
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Appendix 3: Population denominators by age group in Soweto 
Year Age Total population 
2006 < 1 
0-14yrs 
22,382 
344,742 
2007 < 1 
0-14yrs 
21,326 
351,486 
2008 < 1 
0-14yrs 
21,077 
358,076 
2009 < 1 
0-14yrs 
21,627 
364,697 
2010 < 1 
0-14yrs 
23,008 
371,165 
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Appendix 4: HIV prevalence by age-group in Soweto, South Africa 
 2006 2007 2008 2009 2010 
0-4 Prevalence 
Population 
HIV-infected 
HIV-uninfected 
5.05% 
119,179 
6,014 
11,3165 
5.05% 
117,133 
5,914 
111,219 
5.12% 
116,275 
5,956 
110,319 
5.25% 
116,779 
6,386 
110,644 
5.39% 
118,433 
6,386 
112,047 
5-9 Prevalence 
Population 
HIV-infected 
HIV-uninfected 
2.47% 
120,787 
2,981 
117,806 
2.94% 
124,359 
3,653 
120,706 
3.28% 
126,511 
4,147 
122,364 
3.49% 
127,464 
4,453 
123,011 
3.6% 
127,835 
4,603 
123,232 
10-14 Prevalence 
Population 
HIV-infected 
HIV-uninfected 
0.13% 
104,776 
134 
104,642 
0.22% 
109,994 
244 
109,750 
0.13% 
104,776 
133 
104,642 
0.54% 
120,454 
651 
119,803 
0.76% 
124,897 
944 
123,953 
Total Population 
HIV-infected 
HIV-uninfected 
344,742 
9,129 
335,613 
351,486 
9,811 
341,675 
358,076 
10,518 
347,558 
364,697 
11,239 
353,458 
371,165 
11,933 
359,232 
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